http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행성 위암환자에서 Capecitabine/Cisplatin 치료군과 Fluorouracil/Cisplatin 치료군 간의 삶의 질 비교
유희원,신은정,이광자,한현주,손인자 韓國病院藥師會 2004 병원약사회지 Vol.21 No.1
The improvement of medical treatment and anticancer drug has led a complete recovery and prolonged survival time of cancer patients. And recent study of cancer has included evaluation of quality of life. This study was performed to evaluate quality of life between Capecitabine/Cisplatin arm and Fluorouracil/Cisplatin arm. This study was performed in the Seoul National University Hospital from August to October 2003. A total of 8 AGC patients on adjuvant chemotherapy successfully completed this study. Method of study is questionnairing by EORTC QLQ-C30, cancer specific questionnaire. The questionnaire consists of Functional, Symptom, Global health quality of life scale. Patients eligible for this study had histologically confirmed stage III or IV AGC. Patients were to be between 18 and 60 years old, and have performance status of 1. Patients were ineligible if they had a history of 6 months prior or concomitant chemotherapy, radiotherapy. Statistically significant differences favoring the Fluorouracil/Cisplatin arm was noted in the physical scale. In addition, patients in the Fluorouracil/Cisplatin arm reported an improvement in physical functioning after one cycle chemotherapy.
HBV : PE-031 ; Occult HBV infection in Korean blood donors
( Ja Kyung Kim ),( Hye Young Chang ),( Myung Hee Kim ),( Hyun Ok Kim ),( Mi Yeon Choi ),( Soo Youn Lee ),( Hyun Chung Chung ),( Yoo Sung Hwang ),( Kwan Sik Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Blood transfusion can transmit HBV-DNA and cause hepatitis B in blood recipient. Currently, serologic assay for the detection of HBsAg has been used in routine screening test of blood donors. Korea is an endemic area of HBV infection, prevalence of occult hepatitis B can be high. However, donors, who are suspected to have occult HBV infection, have not been evaluated further. We aimed to reveal clinical characteristics and to analyze HBV-DNA in liver tissue in these donors. Methods: Patients who donated blood in Hanmaeum Blood Center between May 16, 2011 and Dec 31, 2011 were enrolled in this study. Blood from these donors was screened HBsAg and HBV-DNA. HBV-DNA was detected by TMA (translationmediated amplification) method with PROCLEIX® TIGRIS® system (Novartis, USA). If a donor, who showed negative HBsAg but positive HBV-DNA, agreed to be evaluated, the donor underwent other serologic tests and liver biopsy. HBV-DNA in liver tissue was detected by direct sequencing. Results: Total 103,017 donors were enrolled. One hundred nineteen donors (0.11%) showed positive HBsAg. Among 102,898 donors with negative HBsAg (99.9%), HBV-DNA was positive in 16 donors (0.016%). Among negative HBsAg and positive HBV-DNA donors, 3 male donors agreed to evaluate further. All three donors had positive anti-HBs and negative HBeAg/anti-HBe, however, only one donor had positive anti-HBc. We confirmed HBV-DNA in liver tissue by PCR. Conclusion: Dual Screening tests with HBsAg and HBV-DNA for blood product can detect occult infection in blood donors. Clinical significance of donors with occult HBV infection needs to evaluated further.
HBV : PE-031 ; Occult HBV infection in Korean blood donors
( Ja Kyung Kim ),( Hye Young Chang ),( Myung Hee Kim ),( Hyun Ok Kim ),( Mi Yeon Choi ),( Soo Youn Lee ),( Hyun Chung Chung ),( Yoo Sung Hwang ),( Kwan Sik Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Blood transfusion can transmit HBV-DNA and cause hepatitis B in blood recipient. Currently, serologic assay for the detection of HBsAg has been used in routine screening test of blood donors. Korea is an endemic area of HBV infection, prevalence of occult hepatitis B can be high. However, donors, who are suspected to have occult HBV infection, have not been evaluated further. We aimed to reveal clinical characteristics and to analyze HBV-DNA in liver tissue in these donors. Methods: Patients who donated blood in Hanmaeum Blood Center between May 16, 2011 and Dec 31, 2011 were enrolled in this study. Blood from these donors was screened HBsAg and HBV-DNA. HBV-DNA was detected by TMA (translationmediated amplification) method with PROCLEIX® TIGRIS® system (Novartis, USA). If a donor, who showed negative HBsAg but positive HBV-DNA, agreed to be evaluated, the donor underwent other serologic tests and liver biopsy. HBV-DNA in liver tissue was detected by direct sequencing. Results: Total 103,017 donors were enrolled. One hundred nineteen donors (0.11%) showed positive HBsAg. Among 102,898 donors with negative HBsAg (99.9%), HBV-DNA was positive in 16 donors (0.016%). Among negative HBsAg and positive HBV-DNA donors, 3 male donors agreed to evaluate further. All three donors had positive anti-HBs and negative HBeAg/anti-HBe, however, only one donor had positive anti-HBc. We confirmed HBV-DNA in liver tissue by PCR. Conclusion: Dual Screening tests with HBsAg and HBV-DNA for blood product can detect occult infection in blood donors. Clinical significance of donors with occult HBV infection needs to evaluated further.
( Hyun Woong Lee ),( Jie Hyun Kim ),( Sang Hoon Ahn ),( Kwang Hyub Han ),( Ja Kyung Kim ),( Yong Han Paik ),( Kwan Sik Lee ),( Chae Yoon Chon ),( Young Myoung Moon ) 대한간학회 2005 Clinical and Molecular Hepatology(대한간학회지) Vol.11 No.3(S)
Background/Objectives: Despite the advancement of treatments for chronic HCV infection, approximately 20% and 50% of patients with HCV genotype 2 or 3 and genotype 1 respectively are unable to achieve sustained virological response (SVR). Interferon (IFN)
( Ja Kyung Kim ),( Kwan Sik Lee ),( Jung Ran Choi ),( Hyun Jung Chung ),( Da Hyun Jung ),( Kyung Ah Lee ),( Jung Il Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Controlled attenuation parameter (CAP) implemented on FibroScan® isreported to be a noninvasive means of detecting steatosis (>10% steatosis). We aimed to evaluate the usefulness of CAP in detecting steatosis among health checkup examinees and to assess its correlation with ultrasonography (US). Methods: Consecutive CAP results were retrospectively collected. Total 280 subjects were included. Results: Fatty liver was detected in 119 (42.5%) subjects by US, whereas it was detected in 160 (57.1%) subjects by CAP. Subjects with S0:S1:S2:S3 steatosis by CAP value were 120:59:58:43, respectively. Mean CAP values were 203.34 ± 28.39 dB/m for S0, 248.83 ± 6.14 dB/m for S1, 274.33 ± 8.53 dB/m for S2, and 322.35 ± 22.20 dB/ m for S3. CAP value was correlated with the body weight (r = 0.404, p < 0.001), BMI (r = 0.445, p < 0.001), and the fatty liver grade by US (r = 0.472, p < 0.001). Among 161 subjects with normal US fi ndings, steatosis was detected in 65 (40.4%) subjects using CAP. Conclusions: CAP seems to be useful in detecting very low grade hepatic steatosis among health checkup examinees. Its role in predicting subjects with risk of metabolic derangement needs to be evaluated.
( Ja Kyung Kim ),( Kwan Sik Lee ),( Jung Ran Choi ),( Hyun Jung Chung ),( Da Hyun Jung ),( Kyung Ah Lee ),( Jung Il Lee ) The Editorial Office of Gut and Liver 2015 Gut and Liver Vol.9 No.3
Background/Aims: The controlled attenuation parameter (CAP) implemented in FibroScan® is reported to be a noninvasive means of detecting steatosis (>10% steatosis). We aimed to evaluate the usefulness of CAP in detecting steatosis among health checkup examinees and to assess its correlation with ultrasonography (US). Methods: Consecutive CAP results were retrospectively collected. A total of 280 subjects were included. Results: Fatty liver was detected in 119 subjects (42.5%) by US, whereas it was detected in 160 subjects (57.1%) by the CAP. The numbers of subjects with S0:S1:S2:S3 steatosis according to the CAP value were 120:59:58:43, respectively. The mean CAP values were 203.34±28.39 dB/m for S0, 248.83±6.14 dB/m for S1, 274.33±8.53 dB/m for S2, and 322.35±22.20 dB/m for S3. CAP values were correlated with body weight (r=0.404, p<0.001), body mass index (r=0.445, p<0.001), and the fatty liver grade by US (r=0.472, p<0.001). Among the 161 subjects with normal US findings, steatosis was detected in 65 subjects (40.4%) using the CAP. Conclusions: The CAP seems to be useful for detecting very low-grade hepatic steatosis in health checkup examinees. Its role in predicting subjects with a risk of metabolic derangement needs to be evaluated. (Gut Liver 2015;9:405-410)
( Ja Hwan Seol ),( Tae Yang Song ),( Se Eun Oh ),( Chanhee Jo ),( Ahreum Choi ),( Byungho Kim ),( Jinyoung Park ),( Suji Hong ),( Ilrang Song ),( Kwan Young Jung ),( Jae Hyun Yang ),( Hwangseo Park ) 생화학분자생물학회(구 한국생화학분자생물학회) 2015 BMB Reports Vol.48 No.12
The eukaryotic genome is packed into chromatin, which is important for the genomic integrity and gene regulation. Chromatin structures are maintained through assembly and disassembly of nucleosomes catalyzed by histone chaperones. Asf1 (anti-silencing function 1) is a highly conserved histone chaperone that mediates histone transfer on/off DNA and promotes histone H3 lysine 56 acetylation at globular core domain of histone H3. To elucidate the role of Asf1 in the modulation of chromatin structure, we screened and identified small molecules that inhibit Asf1 and H3K56 acetylation without affecting other histone modifications. These pyrimidine- 2,4,6-trione derivative molecules inhibited the nucleosome assembly mediated by Asf1 in vitro, and reduced the H3K56 acetylation in HeLa cells. Furthermore, production of HSV viral particles was reduced by these compounds. As Asf1 is implicated in genome integrity, cell proliferation, and cancer, current Asf1 inhibitor molecules may offer an opportunity for the therapeutic development for treatment of diseases. [BMB Reports 2015; 48(12): 685-690]